Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Telix Pharmaceuticals ( (AU:TLX) ).
JPMorgan Chase & Co. and its affiliates have notified Telix Pharmaceuticals Ltd that they have ceased to be a substantial holder in the company as of 20 January 2026, following a series of transactions involving securities lending, collateral arrangements, proprietary trading and prime brokerage-related rehypothecation across multiple JPMorgan entities. The change reduces JPMorgan’s influence over Telix’s voting securities and may marginally alter the company’s shareholder profile, though it does not directly affect Telix’s operations or strategy in the radiopharmaceuticals sector.
The most recent analyst rating on (AU:TLX) stock is a Hold with a A$11.00 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Ltd is an Australia-listed biopharmaceutical company focused on the development and commercialisation of radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products and pipeline target oncology indications using molecularly targeted radiation, positioning the company within the rapidly growing field of nuclear medicine and precision oncology.
Average Trading Volume: 1,907,280
Technical Sentiment Signal: Sell
Current Market Cap: A$3.89B
Learn more about TLX stock on TipRanks’ Stock Analysis page.